Global Genetic Testing Market Analysis
As the foundation of providing superior healthcare lies in diagnosis, genetic testing represents a highly attractive segment in molecular diagnostics market. Genetic testing is a sophisticated form of medical testing for identification of slightest alteration in chromosomes, genes, or proteins that are associated with inherited disorders. The outcome of such tests can confirm or even rule out a suspected genetic condition and help the physician with greater precision towards determining a person’s chance of developing or passing on a genetic disorder. Several hundred genetic tests are currently in use, and more are being developed.
The global genetic testing market is presently in a strong growth trajectory, mainly backed by factors like aging population, increasing incidences for genetic disorders, and rising awareness. In 2010, the genetic testing market worldwide stood at around an estimated mark of US$ 1.5 Billion, which is anticipated to reach at US$ 4 Billion by 2015. Particularly, genetic testing for cancer is likely to emerge as one of the fastest growing segments as private sector and scientific community are actively participating in the oncology-specific areas.
Currently, direct-to-consumer (DTC) genetic testing is the buzz word in market. Companies including deCODE and 23andme have profound effect on the market. The segment is characterized by a sudden inflow of players prompting the healthcare authorities to spark debate on the subject. Our report provides an effective insight into the landscape of DTC genetic tests sector and discusses about the key issues related to the private players and regulatory oversight.
The report, “Global Genetic Testing Market Analysis”, entails key aspects of the global genetic testing market and provides a quantitative analysis of market size and key drivers. It also focuses on key geographies that includes the US, Europe, and Korea. The report also provides information on the state of genetic testing market and ongoing developments in these countries along with state of awareness of general population. Moreover, a prudent analysis on the availability of gene tests for key diseases has also been discussed in the report. Overall, the report is meant to depict a clear and in-depth insight into the genetic testing market that would facilitate the clients to get acquainted with all the necessary information.
The global genetic testing market is presently in a strong growth trajectory, mainly backed by factors like aging population, increasing incidences for genetic disorders, and rising awareness. In 2010, the genetic testing market worldwide stood at around an estimated mark of US$ 1.5 Billion, which is anticipated to reach at US$ 4 Billion by 2015. Particularly, genetic testing for cancer is likely to emerge as one of the fastest growing segments as private sector and scientific community are actively participating in the oncology-specific areas.
Currently, direct-to-consumer (DTC) genetic testing is the buzz word in market. Companies including deCODE and 23andme have profound effect on the market. The segment is characterized by a sudden inflow of players prompting the healthcare authorities to spark debate on the subject. Our report provides an effective insight into the landscape of DTC genetic tests sector and discusses about the key issues related to the private players and regulatory oversight.
The report, “Global Genetic Testing Market Analysis”, entails key aspects of the global genetic testing market and provides a quantitative analysis of market size and key drivers. It also focuses on key geographies that includes the US, Europe, and Korea. The report also provides information on the state of genetic testing market and ongoing developments in these countries along with state of awareness of general population. Moreover, a prudent analysis on the availability of gene tests for key diseases has also been discussed in the report. Overall, the report is meant to depict a clear and in-depth insight into the genetic testing market that would facilitate the clients to get acquainted with all the necessary information.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INTRODUCTION TO GENETIC TESTING
4. GLOBAL GENETIC TESTING MARKET OVERVIEW
4.1 Market Outlook
4.2 DTC Genetic Testing
5. DISEASE-WISE ANALYSIS
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. COUNTRY-LEVEL ANALYSIS
6.1 US
6.2 Europe
6.3 Korea
7. INDUSTRY DEVELOPMENTS
7.1 Recent Product Launches
7.2 Recent Strategic Acquisitions & Agreements
8. EMERGING SECTORS
8.1 Next Generation Sequencing
8.2 Genomic Biomarkers
9. REGULATORY LANDSCAPE
10. COMPETITIVE ASSESSMENT
10.1 Abbott Laboratories
10.2 Qiagen N.V.
10.3 bioMérieux SA
10.4 Hoffmann-La Roche Ltd
10.5 Quest Diagnostics
10.6 Myriad Genetics
2. RESEARCH METHODOLOGY
3. INTRODUCTION TO GENETIC TESTING
4. GLOBAL GENETIC TESTING MARKET OVERVIEW
4.1 Market Outlook
4.2 DTC Genetic Testing
5. DISEASE-WISE ANALYSIS
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. COUNTRY-LEVEL ANALYSIS
6.1 US
6.2 Europe
6.3 Korea
7. INDUSTRY DEVELOPMENTS
7.1 Recent Product Launches
7.2 Recent Strategic Acquisitions & Agreements
8. EMERGING SECTORS
8.1 Next Generation Sequencing
8.2 Genomic Biomarkers
9. REGULATORY LANDSCAPE
10. COMPETITIVE ASSESSMENT
10.1 Abbott Laboratories
10.2 Qiagen N.V.
10.3 bioMérieux SA
10.4 Hoffmann-La Roche Ltd
10.5 Quest Diagnostics
10.6 Myriad Genetics
LIST OF FIGURES
Figure 4-1: Molecular Diagnostics Market (Billion US$), 2008-2011
Figure 4-2: Genetic Testing Market (Billion US$), 2008-2011
Figure 4-3: Forecast for Molecular Diagnostics Market (Billion US$), 2012-2015
Figure 4-4: Forecast for Genetic Testing Market (Billion US$), 2012-2015
Figure 4-5: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-6: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2010)
Figure 6-2: US - Share of Diagnostics Testing in Healthcare Spending
Figure 6-3: Europe - EQA Scheme Participation by Country (Number), 2010
Figure 8-1: Global - Next Generation Sequencing Market (Billion US$), 2011-2015
Figure 8-2: Global - NGS Application by Sector (%)
Figure 8-3: Global - Next Generation Sequencing Market by Player (%), 2010
Figure 10-1: Quest Diagnostics - Sales by Testing (%), 2010
Figure 10-2: Myriad Genetics - Sales by Products (%), 2011
Figure 4-1: Molecular Diagnostics Market (Billion US$), 2008-2011
Figure 4-2: Genetic Testing Market (Billion US$), 2008-2011
Figure 4-3: Forecast for Molecular Diagnostics Market (Billion US$), 2012-2015
Figure 4-4: Forecast for Genetic Testing Market (Billion US$), 2012-2015
Figure 4-5: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-6: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2010)
Figure 6-2: US - Share of Diagnostics Testing in Healthcare Spending
Figure 6-3: Europe - EQA Scheme Participation by Country (Number), 2010
Figure 8-1: Global - Next Generation Sequencing Market (Billion US$), 2011-2015
Figure 8-2: Global - NGS Application by Sector (%)
Figure 8-3: Global - Next Generation Sequencing Market by Player (%), 2010
Figure 10-1: Quest Diagnostics - Sales by Testing (%), 2010
Figure 10-2: Myriad Genetics - Sales by Products (%), 2011
LIST OF TABLES
Table 4-1: Key Companies in DTC Genetic Testing Segment
Table 5-1: Test Availability and Market Size for Key Conditions
Table 6-1: US - FDA Approved Pharmacogenetic Tests
Table 6-2: EU - Key Indicators in Genetics Market
Table 6-3: Europe - Recognized Accreditation Bodies in Key Countries
Table 8-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 9-1: US - Key Elements for Genetic Testing Regulation
Table 9-2: EU - Genetic Testing Regulation in Key Countries
Table 4-1: Key Companies in DTC Genetic Testing Segment
Table 5-1: Test Availability and Market Size for Key Conditions
Table 6-1: US - FDA Approved Pharmacogenetic Tests
Table 6-2: EU - Key Indicators in Genetics Market
Table 6-3: Europe - Recognized Accreditation Bodies in Key Countries
Table 8-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 9-1: US - Key Elements for Genetic Testing Regulation
Table 9-2: EU - Genetic Testing Regulation in Key Countries
